BMG Pharma S.r.l obtained a new indication on Molluscum Contagiosium for CE Marked Proprietary Product Ialuxid® Gel
Monday, February 09, 2015
BMG Pharma S.r.l. today is pleased to announce that it has obtained the inclusion of the Molluscum Contagiosum in the CE Mark Certificate for the product named Ialuxid® Gel, already approved also for the treatment of acne lesions, folliculitis, paronychia, and impetigo.
Ialuxid® Gel shall allow patients to receive the best care possible by using our innovative delivery technology to eliminate Molluscum Contagiosum. This common viral disease has a higher incidence in children, sexually active adults, and those who are immuno-deficientand the infection is most common in children aged one to ten years old.
"BMG Pharma's working team has been strongly committed in the invention and creation of major medical devices, and this is the first approach for our company to MolluscumContagiosum in the device segment.
"We believe this is a short term improvement for the Product" - said Marco Mastrodonato, CEO of BMG Pharma S.r.l. - "We are pleased to offer such new indication to our current partners and provide opportunity for the territories where the product is still available for licensing"
Source:http://www.prnewswire.com/
